To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutics: Importin 7 (IPO7); MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1)

Cancer

INDICATION: Cancer

In vitro and mouse studies suggest a peptide inhibitor of IPO7 binding to MAPK1 or MAPK3 could help

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE